Am J Transplant, Volume 18, Suppl 3 Archives - Page 76 of 211 - ATC Abstracts

2018 American Transplant Congress
Variation in Hypothermic Machine Perfusion Utilization and Clinical Outcomes for Deceased-Donor Kidneys
V. Krishnamoorthy,¹ S. Wunsch,² K. O'Connor,² M. Souter.³
¹Anesthesiology, Duke University, Durham, NC; ²LifeCenter Northwest, Bellevue, WA; ³Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.
Introduction:Hypothermic machine perfusion (HMP) has been shown to be an effective method for preserving kidney allografts from deceased donors (1), but data suggests that low-risk…
2018 American Transplant Congress
Living-Donor Preemptive Kidney Transplant Timing Calculator: An Online Decision Support Tool
M. Barah,¹ M. Kurt,² A. Khojandi,¹ B. Tanriover.³
¹Industrial and Systems Engineering, Univeristy of Tennessee, Knoxville, TN; ²Economic and Data Sciences, Merck Research Labs, North Wales, PA; ³Division of Nephrology, UT Southwestern Medical Center, Dallas, TX.
Purpose: Optimal glomerular filtration rate (GFR) and timing for living preemptive kidney transplantation (PKT) is not well studied.Method: We developed an online engine to calculate…
2018 American Transplant Congress
Myeloid-Derived Suppressor Cells Suppress with Enhanced Donor Specificity in Donor ECDI-SP Treated Recipients
L. Zhang, J. Wang, Z. Zhang, X. Luo.
Northwestern University Feinberg School of Medicine, Chicago.
Introduction: Published data in cancer models have shown that myeloid-derived suppressor cells (MDSCs) can induce antigen-specific CD8 T cell tolerance and promote tumor escape (Nagaraj…
2018 American Transplant Congress
The Role of Donor-Derived Cell-Free DNA in Identification of Injury in Kidney Allografts with Antibody-Mediated Rejection and De Novo DSA
H. Zhang,¹ L. Liu,¹ C. Zheng,² X. Li,¹ Q. Fu,¹ J. Li,¹ Q. Su,¹ H. Huang,¹ M. Ye,² C. Wang.¹
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²BGI-Guangzhou Medical Laboratory, BGI-Shenzhen, Guangzhou, China.
Objectives: To evaluate the capacity of donor-derived cell-free DNA (dd-cfDNA) in the identification of injury in kidney allografts with antibody-mediated rejection and de novo DSA.Methods:…
2018 American Transplant Congress
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
B. Nashan,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was designed to compare efficacy, safety and outcomes on renal function [GFR] of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A…
2018 American Transplant Congress
Eplet Mismatches and De Novo Donor Surface Antibody Development in Pediatric Renal Transplant Recipients
E. Blanchette,¹ M. Bradford,¹ P. Warner,² C. Blosser,³ I. Gimferrer,² J. Smith.¹
¹Seattle Children's Hospital, Seattle; ²Bloodworks Northwest, Seattle; ³UW Medicine, Seattle.
Background: De novo donor surface antibody (dnDSA) development is arguably the first step in the natural history of allograft injury secondary to humoral alloimmunity. This…
2018 American Transplant Congress
Higher Early Post-Liver Transplant Mortality in Recipients with Severe Alcoholic Hepatitis versus Alcoholic Cirrhosis
B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R. Ghobrial, Z. Li, N. Terrault.
UCSF, SF; Mt Sinai, NYC; Iowa, Iowa; UW, Madison; Hopkins, Baltimore; Ochsner, Jefferson; USC, LA; Houston Methodist, Houston; Swedish, Seattle; Maryland, Baltimore; UPenn, Philadelphia; NW, Chicago; Rush, Chicago.
INTRODUCTIONThe American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) is a multicenter cohort from 8 UNOS regions studying early liver transplant (LT) for…
2018 American Transplant Congress
Development of a Novel Assay System for Ex Vivo T-Cell Mediated Rejection Responses in Intestinal Grafts
S. Okano,^1,2 K. Abu-Elmagd,² D. Kish,¹ K. Keslar,¹ M. Fujiki,² G. Costa,² C. Miller,² W. Baldwin,¹ R. Fairchild,¹ K. Hashimoto.²
¹Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; ²General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH.
In intestinal transplantation, the intestinal allograft (IA) presents a formidable challenge for control of alloimmune responses due to constitutive MHC class II expression by intestinal…
2018 American Transplant Congress
Hematopoietic Cell Kinase (Hck) Regulates Effector and Regulatory T Cell (Treg) Function
S. Farouk,¹ C. Wei,¹ B. Das,² P. Cravedi,¹ B. Murphy.¹
¹Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mt. Sinai, New York, NY; ²Department of Pharmacological Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY.
Background: We found that upregulation of Hck mRNA expression, an Src family tyrosine kinase, in surveillance graft biopsies of kidney transplant patients associates with an…
2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
E. Woodle,¹ D. Kaufman,² A. Shields,¹ J. Leone,³ A. Wiseman,⁴ A. Matas,⁵ P. West-Thielke,⁶ E. King,¹ R. Alloway.¹
¹U Cincinnati, Cincinnati; ²U Wisconsin, Madison; ³Tampa General, Tampa; ⁴U Colorado, Denver; ⁵U Minnesota, Minneapolis; ⁶UIC, Chicago.
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…